Damora Therapeutics, Inc.

Damora Therapeutics is a biopharmaceutical company that develops treatments for blood disorders. The company expanded its product pipeline by acquiring three product candidates designed to treat myeloproliferative neoplasms (MPNs), which are chronic bone marrow disorders. Damora's primary product candidate is DMR-001, which targets mutant forms of the calcium binding protein calreticulin (mutCALR). The company has licensed exclusive worldwide development and commercialization rights for DMR-001 from Paragon Therapeutics, Inc. under an agreement dated October 7, 2025. Damora plans to develop DMR-001 to treat essential thrombocythemia (ET), an MPN characterized by excessive platelet production, and myelofibrosis (MF), an MPN involving the overproduction of blood cells and fibrous tissue in the bone marrow and spleen. Approximately 25% of ET cases and 35% of MF cases are caused by mutCALR, rather than mutations in Janus-associated kinase 2 (JAK2). DMR-001 is designed to selectively target cells expressing mutCALR, aiming to avoid the side effects of non-specific cytoreductive drugs. It was also designed for increased affinity, potency, and a prolonged half-life compared to other mutCALR-targeting antibodies in development. Damora also holds options to license exclusive worldwide development and commercialization rights from Paragon for two additional mutCALR-targeting product candidates, DMR-002 and DMR-003. The company intends to submit an Investigational New Drug Application (IND) or Clinical Trial Application (CTA) for DMR-001 and DMR-002 in mid-2026 and the second half of 2026, respectively, and for DMR-003 in 2027.